Accreditation | The Medical Professionalism Project

Learning Objectives

At the end of this enduring educational activity providers should be able to:

1 Participate in a dialogue about what constitutes medical professionalism.

2 Recognize factors that influence professional behavior.

3 Recognize unprofessional behaviors in themselves and in others.

4 Access tools that aid in maintaining and improving professional behaviors.

In support of improving patient care, Duke University Health System Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Category 1: Duke University Health System Department of Clinical Education and Professional Development designates this enduring educational activity for a maximum of 6 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nursing CE: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 6 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Duke University Health System Clinical Education and Professional is accredited by the International Association for Continuing Education and Training (IACET) and is authorized to issue the IACET CEU. Duke University Health System Clinical Education and Professional is authorized by IACET to offer 0.6 CEUs for this program.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory The Medical Professionalism Project met the requirements as an MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity

Allergy and Immunology
Anesthesiology
Family Medicine
Nuclear Medicine
Ophthalmology
Physical Medicine and Rehabilitation
Preventive Medicine
Psychiatry and Neurology
Radiology
Thoracic Surgery
Urology

Through the ACCME MOC recognition program, successful completion of this CME activity enables the participant to earn 6.0 MOC points in the American Board of Anesthesiology (ABA) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purposes of granting ABA MOC points.

Through the ACCME MOC recognition program, successful completion of this CME activity enables the participant to earn 6.0 MOC points in the American Board of Internal Medicine (ABIM) MOC program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purposes of granting ABIM MOC points.

If you have any questions regarding accreditation or the course, please email us at contact@professionalismproject.com.

The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of this CE activity:

Dan Ariely, PhD

Don Bradley, MD, MHS-CL

Edward Buckley, MD

Frank DeMarco, MSN, RN

Karen Frush, MD

Karol Harshaw-Ellis, MSN, DNP

Ross McKinney, Jr., MD

Diana B. McNeill, MD

Yael Melamede

Colin O’Leary, MD

Rebecca Ortega, MHA

Tom A. Owens, MD

Philip Rosoff, MD, MA

Kevin A. Schulman, MD, MBA

Megan C. Turner, MD, MHS

Damon S. Tweedy, MD

Kevin P. Weinfurt, PhD

The following speakers and/or planning committee members have indicated that they have the following relationship(s) with industry to disclose:

Allan D. Kirk, MD, PHD – Bristol-Myers Squibb: Principal Investigator; MedBlue Data: Stockholder, Other; MedBlue Incubator: Other; Semma Therapeutics: Stockholder.

Adrienne Lloyd, MHA, FACHE – Medical Group Management Association: Speaker, Consultant.

Manesh R. Patel, MD – AstraZeneca: Principal Investigator, Advisory Board; Bayer: Principal Investigator, Advisory Board; Heartflow: Principal Investigator, Consultant; Janssen: Principal Investigator, Advisory Board; Mytonomy, Advisory Board; Procyrion, Principal Investigator, Advisory Board.

William J. Richardson, MD – Pfizer, Consultant; Brain Lab, Speaker; Mobius, Speaker, Consultant; Spine Wave, Consultant.

Michael “Buz” Waitzkin, JD – Orbit Genomics: Advisory Board.

Tracy Y. Wang, MD, MHS, MSC – AstraZeneca: Principal Investigator, Consultant; Bristol-Myers Squibb: Principal Investigator; CryoLife: Principal Investigator, Consultant; Chiesi: Principal Investigator; Merck: Principal Investigator; Portola: Principal Investigator; Regeneron: Principal Investigator; Sanofi: Consultant.

S. Yousuf Zafar, MD, MHS – AstraZeneca: Other; AIM Specialty Health: Advisory Board; SamFund: Advisory Board; Vivor, LLC: Advisory Board; Shattuck Labs (spouse): Employee.

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Participate in dialogue about what constitutes medical professionalism.
Recognize factors that influence professional behavior.
Recognize unprofessional behaviors in myself and in others.
Access tools that aid in professional behavior identification and improvement.

Login

Reset password

Redeem Credits

Please rate the impact of the following objectives:

Please rate the projected impact of this activity on your knowledge/competence, skills/strategy, performance, and patient outcomes*:

Target Audience

Learning Objectives

Accreditation statement

Disclosures

The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of this CE activity:

The following speakers and/or planning committee members have indicated that they have the following relationship(s) with industry to disclose: